Bacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States
Gherman Uritskiy
Bacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States
Marthandan Mahalingam
Bacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States
Himanshu Batra
Bacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States
Subhash Chand
Bacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States
Hung V Trinh
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States; Laboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
Charles Beck
Department of Molecular Genetics and Microbiology, Duke University, Durham, United States
Woong-Hee Shin
Department of Biological Sciences, Purdue University, West Lafayette, United States; Department of Chemistry Education, Sunchon National University, Suncheon, Republic of Korea; Department of Advanced Components and Materials Engineering, Sunchon National University, Suncheon, Republic of Korea
Wadad Alsalmi
Bacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States
Gustavo Kijak
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States; Laboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
Leigh A Eller
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States
Jerome Kim
Laboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
Daisuke Kihara
Department of Biological Sciences, Purdue University, West Lafayette, United States; Department of Computer Science, Purdue University, West Lafayette, United States
Sodsai Tovanabutra
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States; Laboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
Guido Ferrari
Department of Molecular Genetics and Microbiology, Duke University, Durham, United States
Merlin L Robb
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States
Mangala Rao
Laboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
A productive HIV-1 infection in humans is often established by transmission and propagation of a single transmitted/founder (T/F) virus, which then evolves into a complex mixture of variants during the lifetime of infection. An effective HIV-1 vaccine should elicit broad immune responses in order to block the entry of diverse T/F viruses. Currently, no such vaccine exists. An in-depth study of escape variants emerging under host immune pressure during very early stages of infection might provide insights into such a HIV-1 vaccine design. Here, in a rare longitudinal study involving HIV-1 infected individuals just days after infection in the absence of antiretroviral therapy, we discovered a remarkable genetic shift that resulted in near complete disappearance of the original T/F virus and appearance of a variant with H173Y mutation in the variable V2 domain of the HIV-1 envelope protein. This coincided with the disappearance of the first wave of strictly H173-specific antibodies and emergence of a second wave of Y173-specific antibodies with increased breadth. Structural analyses indicated conformational dynamism of the envelope protein which likely allowed selection of escape variants with a conformational switch in the V2 domain from an α-helix (H173) to a β-strand (Y173) and induction of broadly reactive antibody responses. This differential breadth due to a single mutational change was also recapitulated in a mouse model. Rationally designed combinatorial libraries containing 54 conformational variants of V2 domain around position 173 further demonstrated increased breadth of antibody responses elicited to diverse HIV-1 envelope proteins. These results offer new insights into designing broadly effective HIV-1 vaccines.